Novocure (NVCR) Misses Q1 EPS by 6c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Novocure (NVCR) Misses Q1 EPS by 6c, Revenues Miss

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

April 29, 2021 6:00 AM EDT

Quarterly net revenues of $134.7 million with 80% gross margin

Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven by COVID-19, as well as continued progress across the companys clinical and product development programs. Novocure is a global oncology company working to... More